Innovent Biologics Financials
| IVBXF Stock | USD 4.85 0.24 4.72% |
Innovent |
Understanding current and past Innovent Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Innovent Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Innovent Biologics' assets may result in an increase in income on the income statement.
Innovent Biologics Stock Summary
Innovent Biologics competes with Telix Pharmaceuticals, Keros Therapeutics, MAIA Biotechnology, Genscript Biotech, and Oxford Nanopore. Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 168 Dongping Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.innoventbio.com |
| Phone | 86 512 6956 6088 |
| Currency | USD - US Dollar |
Innovent Biologics Key Financial Ratios
There are many critical financial ratios that Innovent Biologics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Innovent Biologics reports annually and quarterly.| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Beta | 0.16 | |||
| Z Score | 2.4 |
Innovent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innovent Biologics's current stock value. Our valuation model uses many indicators to compare Innovent Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innovent Biologics competition to find correlations between indicators driving Innovent Biologics's intrinsic value. More Info.Innovent Biologics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innovent Biologics' earnings, one of the primary drivers of an investment's value.Innovent Biologics Systematic Risk
Innovent Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Innovent Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Innovent Biologics correlated with the market. If Beta is less than 0 Innovent Biologics generally moves in the opposite direction as compared to the market. If Innovent Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Innovent Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Innovent Biologics is generally in the same direction as the market. If Beta > 1 Innovent Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Innovent Biologics November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Innovent Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Innovent Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Innovent Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Innovent Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Innovent Biologics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 24.34 | |||
| Value At Risk | (7.81) | |||
| Potential Upside | 5.48 |
Complementary Tools for Innovent Pink Sheet analysis
When running Innovent Biologics' price analysis, check to measure Innovent Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovent Biologics is operating at the current time. Most of Innovent Biologics' value examination focuses on studying past and present price action to predict the probability of Innovent Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovent Biologics' price. Additionally, you may evaluate how the addition of Innovent Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |